NCT02776371View on ClinicalTrials.gov

Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori

PHASE4CompletedINTERVENTIONAL

Enrollment

301

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

January 31, 2018

Study Completion Date

February 28, 2018

Conditions

Helicobacter Pylori Eradication Rate

Interventions

DRUG

Modified non-clarithromycin triple therapy

H. pylori infected patients treated with 10 mg rabeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 14 days.

DRUG

Sequential therapy

H. pylori infected patients treated with 10 mg rabeprazole and 1 g amoxicillin, twice daily for 7 days, followed by 10 mg rabeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 7 days.

Trial Locations (1)

250012

Department of Gastroenterology, Qilu Hospital, Shandong University, Jinan

All Listed Sponsors

lead

Shandong University

OTHER

NCT02776371 - Modified Non-clarithromycin Triple Therapy in Eradicating Helicobacter Pylori | Biotech Hunter | Biotech Hunter